We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Agrees to License Its Antiviral Pill to Medicines Patent Pool
Merck Agrees to License Its Antiviral Pill to Medicines Patent Pool
Merck has struck a licensing pact with the Medicines Patent Pool (MPP), a United Nations-supported public health organization serving the developing world, to expand access to its experimental COVID-19 antiviral pill, molnupiravir, co-developed with Ridgeback Biotherapeutics.